High Purity Ceftiofur HCl API CAS 103980-44-5

• Standard: USP/Ep/Bp
• Transport Package: 25 Kg/Drum
• Specification: 25 Kg/Drum
• Trademark: SINOPHARM
• Origin: China
• Model NO.: USP/EP/BP
• Production Capacity: 1000000 Kg/Year

Product Description

Ceftiofur hydrochloride is a third-generation cephalosporin for animals. It is mainly used to treat infectious diseases of pigs, cattle, horses, dogs and day-old chicks caused by sensitive bacteria.
 

Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987. It is marketed by pharmaceutical company Zoetis as Excenel, Naxcel, and Excede and is also the active ingredient in that company's Spectramast LC (lactating cow formulation) and Spectramast DC (dry cow formulation) product.

It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against both Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported. 

Ceftiofur sodium / ceftiofur hydrochloride is suitable for the treatment of bovine respiratory diseases (transport fever, pneumonia) caused by Pasteurella hemolyticus, Pasteurella multocida, Haemophilus typhimurium, lactation and non-lactation use. Ceftiofur sodium can be used for horse respiratory diseases caused by the subspecies of Streptococcus equi subsp., and ceftiofur hydrochloride can be used for rot rot disease of cattle. For pigs, both can be used to control/treat bacterial pneumonia. Ceftiofur sodium is also suitable for respiratory diseases in sheep and goats and sensitive urinary tract infections in dogs. It also has potential therapeutic effects on other small animal infections and can be used in newborn chicks and turkeys.

The metabolite desfurolyceftiofur also has antibiotic activity. The two compounds are measured together to measure for antibiotic activity in milk (alongside other antibiotics). 

About Us:



China Sinopharm International (Shanghai) Co., Ltd. is a comprehensive commercial service enterprise centering international pharmaceutical business.

It is a wholly-owned subsidiary under China Sinopharm International Corporation and is affiliated to China National Pharmaceutical Group Corporation (referred to as "Sinopharm Group"), a Fortune Global 500. Founded in 1985, the company has an net asset of nearly 200 million yuan. It has complete commercial facilities and 23,000 square meters of properties including an office building and shopping malls in Shanghai's West Nanjing Road commercial area and multiple warehouses. International business are carried out based on the platforms of Sinopharm Group and Sinopharm International Pharmaceutical and aims to spread China's high-quality pharmaceutical products and services to the world.

Through close cooperation with major domestic pharmaceutical companies, high-quality pharmaceutical products and overall solutions are provided to overseas customers. We are a well-known pharmaceutical enterprise in China with partners extending to more than 80 countries and regions around the world.